Non-Small Cell Lung Cancer (NSCLC) Clinical Trials

• Age 18-75 years old, gender is not limited;

• Histologically confirmed Stage III non-small cell lung cancer (AJCC Stage 8th edition)

• The tumor is resectable after assessment by the attending surgeon

• EGFR/ALK mutation negative or unknown (unknown only for squamous non-small cell lung cancer)

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

• No previous treatment received

• At least 1 measurable lesion as defined by RECIST v1.1

• Be able to provide the Informed Consent Form (ICF), and be able to understand and agree to abide by the research requirements and assessment schedule

• Good organ function; • Patients have not received blood transfusion or growth factor support therapy ≤ 14 days prior to sample collection during the screening period and: Absolute neutral cell count (ANC) ≥1.5 x 109/L Platelet ≥100 x 109/L Hemoglobin ≥90 g/L • Calculated creatinine clearance (CrCl) (Cockcroft-Gault formula) creatinine clearance ≥ 45 mL/min Serum total bilirubin ≤1.5 × upper limit of normal (ULN) (patients with Gilbert\'s syndrome must have total bilirubin \< 3 × ULN) AST and ALT≤ 2.5 x ULN Patients who did not receive anticoagulant therapy: International standardized ratio or activated partial thromboplastin time ≤ 1.5 × ULN

⁃ Women of childbearing age must take a serum pregnancy test within 3 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must agree to use highly effective methods of contraception during the study period and for 120 days after the last dose of the study drug